Key result
Metastatic malignancy cases show rapid-onset fatal heart failure despite normal baseline cardiac assessments.
Why the study?
A potential bidirectional relationship between heart failure and cancer progression remains underexplored despite recognition of cancer therapy-related cardiac dysfunction.
Case Report (n=2)
New-onset heart failure occurring alongside rapidly progressive malignancy highlights a potential bidirectional interaction with important prognostic implications and high short-term mortality.
Answers are grounded in this paper and cite their sources.
May signal rapid HF risk in metastatic cancer; leaves open bidirectional interactions for prospective confirmation.
The interaction between malignancy and cardiovascular disease is increasingly recognized in cardiooncology.While cancer therapy-related cardiac dysfunction is well established, a potential bidirectional relationship between heart failure (HF) and cancer progression remains underexplored.We present the cases of two patients without known cardiovascular disease who developed new-onset HF in temporal association with rapidly progressive metastatic malignancies.A 65-year-old man with metastatic pancreatic adenocarcinoma developed severe left ventricular (LV) systolic dysfunction with a left ventricular ejection fraction (LVEF) of 30%, apical akinesis, and suspected LV thrombus after a previously normal cardiac evaluation.A 44-year-old man with metastatic esophageal squamous cell carcinoma developed severe LV systolic dysfunction (LVEF 25-30%) with global hypokinesia, also following a normal baseline cardiac assessment.In both cases, baseline electrocardiography, troponin levels, and echocardiography were normal, whereas B-type natriuretic peptide (BNP) levels became elevated during rapid tumor progression.Both patients experienced rapid clinical deterioration and died within weeks of diagnosis.These cases highlight a potential interaction between aggressive malignancy and cardiac dysfunction, possibly mediated by inflammatory, metabolic, and neurohormonal mechanisms.Conversely, HF may adversely affect oncologic outcomes by reducing physiological reserve and limiting therapeutic options.Although causality cannot be established from these observations, new-onset HF occurring alongside rapidly progressive malignancy may represent an underrecognized clinical phenomenon with important prognostic implications.
No takes yet. Share an insight, caveat, or question.
Djerouni et al. (2026) conducted a case report in Metastatic malignancy and new-onset heart failure (n=2). Rapidly progressive metastatic malignancies was evaluated on New-onset heart failure and clinical deterioration. Two patients with metastatic malignancies rapidly developed new-onset severe heart failure following normal baseline cardiac assessments and died within weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: